+56.2%
EWZ vs MRNA
+561.6%
-505.4%
-57.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | -2.2% | +1.5% | -0.7% |
| 7D | +6.5% | +5.5% | +1.0% | +6.4% |
| 30D | +4.8% | +158.7% | -153.9% | +1.3% |
| 3M | +9.9% | +182.1% | -172.2% | +5.7% |
| 6M | +1.9% | +151.8% | -149.9% | -1.7% |
| YTD | +20.3% | +393.6% | -373.3% | +14.2% |
| 1Y | +35.6% | +499.5% | -463.8% | +27.9% |
| 3Y | +43.4% | +29.3% | +14.1% | +37.6% |
| 5Y | +55.9% | -65.1% | +121.0% | +47.8% |
| All | +56.2% | +561.6% | -505.4% | +58.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling